Truist Securities Reiterates Buy on Kymera Therapeutics, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Kymera Therapeutics but slightly lowered the price target from $54 to $53.

November 01, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Kymera Therapeutics but slightly reduces the price target from $54 to $53.
The reiteration of a Buy rating suggests continued confidence in Kymera Therapeutics, which is positive. However, the slight reduction in the price target from $54 to $53 may indicate a minor adjustment in expectations, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100